Metabolic Drivers of Alzheimer's Disease: Integrating brain Hypometabolism, insulin Resistance, and systemic dysregulation.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanistic theoretical framework with no new human empirical data or systematic search protocol.
PubMed 41876030 · doi:10.1016/j.yfrne.2026.101248
What was done
Narrative review synthesizing evidence on the metabolic hypothesis of Alzheimer's disease, focusing on cerebral glucose hypometabolism, brain insulin resistance, mitochondrial dysfunction, APOE ε4 lipid defects, and gut-brain axis interactions.
What was found
The abstract reports no quantitative data, sample sizes, or statistical findings. It presents a conceptual framework wherein cerebral glucose hypometabolism arises decades before clinical symptoms and establishes a self-reinforcing pathological cycle with insulin resistance, amyloid-β, tau, neuroinflammation, and synaptic loss.
Why it matters
Argues for shifting Alzheimer's disease therapeutic development away from late-stage single-target protein clearance toward early multimodal strategies that restore metabolic homeostasis.
Limits
Narrative synthesis with no systematic review methodology, risk of bias assessment, or primary empirical data reported in the abstract.
Cited by
- supports Alzheimer's disease is biologically characterized in many ways as type 3 diabetes.